IE40187B1 - Process for the preparation of pyrogen-free sub-unit vaccine - Google Patents

Process for the preparation of pyrogen-free sub-unit vaccine

Info

Publication number
IE40187B1
IE40187B1 IE2141/74A IE214174A IE40187B1 IE 40187 B1 IE40187 B1 IE 40187B1 IE 2141/74 A IE2141/74 A IE 2141/74A IE 214174 A IE214174 A IE 214174A IE 40187 B1 IE40187 B1 IE 40187B1
Authority
IE
Ireland
Prior art keywords
active agent
density gradient
pyrogen
preparation
vol
Prior art date
Application number
IE2141/74A
Other versions
IE40187L (en
Original Assignee
Flockhart & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flockhart & Co filed Critical Flockhart & Co
Publication of IE40187L publication Critical patent/IE40187L/en
Publication of IE40187B1 publication Critical patent/IE40187B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A liquid medium which contains inactivated ether-sensitive complete virus is introduced into a zonal ultracentrifuge with continuous charging, provided with a density gradient solution which contains a haemolytic surface-active agent. The virions enter the density gradient and are cleaved by the surface-active agent. The fractions with the antigenic subunits are isolated. The preferred product of this process is an influenza virus subunit vaccine which is obtained using a density gradient solution in which the concentration of the surface-active agent is about 1 % vol./vol. [GB1486557A]
IE2141/74A 1973-10-18 1974-10-17 Process for the preparation of pyrogen-free sub-unit vaccine IE40187B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB48685/73A GB1486557A (en) 1973-10-18 1973-10-18 Process for the preparation of pyrogen-free sub-unit vaccine

Publications (2)

Publication Number Publication Date
IE40187L IE40187L (en) 1975-04-18
IE40187B1 true IE40187B1 (en) 1979-03-28

Family

ID=10449549

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2141/74A IE40187B1 (en) 1973-10-18 1974-10-17 Process for the preparation of pyrogen-free sub-unit vaccine

Country Status (15)

Country Link
JP (1) JPS5082228A (en)
AT (1) AT334524B (en)
BE (1) BE821175A (en)
CA (1) CA1050886A (en)
CH (1) CH611518A5 (en)
DE (1) DE2449530C2 (en)
DK (1) DK138581B (en)
FR (1) FR2248054B1 (en)
GB (1) GB1486557A (en)
IE (1) IE40187B1 (en)
IL (1) IL45870A (en)
NL (1) NL181553C (en)
NO (1) NO142024C (en)
SE (1) SE426439B (en)
ZA (1) ZA746398B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK276380A (en) * 1979-07-09 1981-01-10 Univ Iowa State Res Found Inc PROCEDURE FOR THE PREPARATION OF A VACCINE AGAINST INFECTIOUS KVEG-RHINOTRACHEITIS
FR2470795A1 (en) * 1979-12-07 1981-06-12 Pasteur Institut PROCESS FOR THE PURIFICATION OF PARTICLES OF BIOLOGICAL ORIGIN, IN PARTICULAR OF THE SURFACE ANTIGEN OF HEPATITIS B VIRUS (AGHBS) AND THE PRODUCTS OBTAINED
FR2475572A1 (en) * 1980-02-11 1981-08-14 Pasteur Institut PROCESS FOR OBTAINING LIPID ENVELOPE VIRUS FRAGMENTS, PARTICULARLY ANTIGENS USED AS VACCINES, PRODUCTS OBTAINED AND APPLICATIONS
FR2483779A1 (en) 1980-06-05 1981-12-11 Synthelabo PROCESS FOR ISOLATING VIRAL GLYCOPROTETIC ANTIGENS AND APPLICATION THEREOF TO VACCINE PREPARATION
DE19938767C2 (en) * 1999-08-16 2002-10-24 Tad Pharma Gmbh subunit vaccines
CN1253207C (en) * 2000-10-02 2006-04-26 葛兰素史密丝克莱恩生物有限公司 Split enveloped virus preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3519400A (en) * 1967-01-25 1970-07-07 Atomic Energy Commission Method of centrifugal separation and recovery of chemical species utilizing a liquid medium

Also Published As

Publication number Publication date
DK543974A (en) 1975-06-16
FR2248054A1 (en) 1975-05-16
CH611518A5 (en) 1979-06-15
NL7413642A (en) 1975-04-22
SE7413113L (en) 1975-04-21
NO142024B (en) 1980-03-10
DE2449530C2 (en) 1985-08-08
NL181553C (en) 1987-09-16
DK138581C (en) 1979-03-12
GB1486557A (en) 1977-09-21
AU7444974A (en) 1976-04-29
CA1050886A (en) 1979-03-20
NL181553B (en) 1987-04-16
AT334524B (en) 1976-01-25
FR2248054B1 (en) 1978-07-28
IL45870A (en) 1978-03-10
DE2449530A1 (en) 1975-04-30
ATA835074A (en) 1976-05-15
BE821175A (en) 1975-04-17
DK138581B (en) 1978-10-02
NO142024C (en) 1980-06-18
JPS5082228A (en) 1975-07-03
IE40187L (en) 1975-04-18
SE426439B (en) 1983-01-24
NO743758L (en) 1975-05-12
ZA746398B (en) 1976-06-30
IL45870A0 (en) 1974-12-31

Similar Documents

Publication Publication Date Title
SE9102976D0 (en) HYBRID DNA VECTORS, SINGLE ORGANISMS AND BACTERIA FOR USE FOR PRODUCTION OF HIV PROTEINS AND PEPTIDES
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
ATA852374A (en) PROCESS FOR THE PREPARATION OF NEW 1,2-BENZISOXAZOLE DERIVATIVES
IE40187B1 (en) Process for the preparation of pyrogen-free sub-unit vaccine
ES8104405A1 (en) Influenza virus vaccines, process for preparing them and process for propagating influenza viruses.
Bicker et al. Enzymatic aziridine synthesis from β amino-alcohols—a new example of endogenous carcinogen formation
GB1292803A (en) Improvements relating to the production of antigens
GB1461188A (en) Live influenza virus vaccines and preparation thereof
IE39521B1 (en) Process for the preparation of 2,2,6,6,-tetramethyl-4-oxopiperidine
GB1488800A (en) Influenza vaccines
GB1469901A (en) Process for obtaining virus proteins
DK115349B (en) Method for preparing a vaccine-inactivated virus suspension containing a virus isolated from in vitro cultured kidney cells of a puppy suffering from rhinitis or bronchopneumonia.
GB1252092A (en)
DK136827B (en) 17beta-hydroxy-3-oxo-4,6-steroid diene-17alpha-methylmalonic acid derivatives for use as intermediates for the preparation of 17-spirolactones and process for the preparation of the intermediates.
CH611338A5 (en) Process for the preparation of inactivated HB-Ag vaccines
FR2261779A1 (en) Anti-rabies vaccine - obtd. from rabies virus grown on foetal calf kidney cells in a synthetic serum-free medium
ES8107024A1 (en) Feline infectious peritonitis vaccine and process for its preparation.
ATE4637T1 (en) PENTADECAPEPTIDE, PROCESS FOR ITS PREPARATION AND IMMUNSIFYING AGENT.
GB958574A (en) Clostridium perfringens ª‰-toxoid vaccines
GB1436323A (en) Cell and virus culture systems
DK138320B (en) Analogous process for the preparation of 1,4-benzodiazepine derivatives or pharmaceutically usable acid addition salts thereof.
FR2290220A2 (en) Antirabies vaccine for veterinary use - prepd. by cultivating virus on foetal calf kidney cells in medium of hydrolysed lactalbumin and calf serum
USD235586S (en) Joel stearman
AT340403B (en) PROCESS FOR THE PREPARATION OF 2-NITROINDAN-1,3-DIONE DERIVATIVES
SE7910489A (en) ISOINDOLINE ASSOCIATIONS AND PROCEDURES FOR THE PREPARATION THEREOF